Huan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huan Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Canxia Xu
Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China
1 shared publication - Guowei Wang
Center for Experimental Medicine Third Xiangya Hospital Central South University Changsha 410013 China csu.edu.cn
1 shared publication - Jiahui Lin
Digestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518107, China
1 shared publication Jingshu Chi
Department of Gastroenterology, Third Xiangya Hospital, Central South University., Changsha, Hunan, People’s Republic of China
1 shared publication- Ju Luo
Department of Gerontology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China
1 shared publication Lin Xu
Department of Endocrinology, Sir Run Run Hospital Nanjing Medical University Nanjing Jiangsu China
1 shared publication
Latest Publications
- 4 November 2025
- Published by Wiley in Luminescence
- Vol. 40 (11) , e70343
IDIC‐Based Phototheranostic Nanoparticles for NIR Light‐Excited Immuno‐Phototherapy
The development of single component, multifunctional phototheranostic platforms remains a crucial objective in precision cancer therapy. Here, we design near‐infrared (NIR) light‐activated nanoparticles (NPs) by assembling IDIC with DSPE‐PEG‐NH 2 to achieve high photothermal conversion efficiency, reactive oxygen species generation, and biocompatibility. The resulting IDIC NPs exhibit strong NIR absorption and fluorescence, high photostability, and good aqueous stability. Upon 635‐nm laser irradiation, they reach a photothermal conversion efficiency of 52.8% and a singlet oxygen quantum yield of 43.0%, enabling synergistic photothermal and photodynamic therapy. In vitro, IDIC NPs show negligible dark toxicity but induce potent tumor cell ablation upon irradiation through mitochondrial membrane disruption and immunogenic cell death, evidenced by calreticulin exposure, HMGB1 release, and ATP secretion. In vivo, they enable effective NIR imaging, inhibit tumor growth, prolong survival, and cause minimal systemic toxicity. Laser‐treated tumors exhibit enhanced apoptosis, reduced proliferation, and macrophage polarization toward an M1 phenotype. These findings establish IDIC NPs as a robust, single‐component nanotheranostic agent integrating NIR imaging, photothermal/photodynamic synergy, and immune activation for cancer treatment.
- 4 November 2025
- Published by Wiley in Luminescence
- Vol. 40 (11) , e70343
IDIC‐Based Phototheranostic Nanoparticles for NIR Light‐Excited Immuno‐Phototherapy
The development of single component, multifunctional phototheranostic platforms remains a crucial objective in precision cancer therapy. Here, we design near‐infrared (NIR) light‐activated nanoparticles (NPs) by assembling IDIC with DSPE‐PEG‐NH 2 to achieve high photothermal conversion efficiency, reactive oxygen species generation, and biocompatibility. The resulting IDIC NPs exhibit strong NIR absorption and fluorescence, high photostability, and good aqueous stability. Upon 635‐nm laser irradiation, they reach a photothermal conversion efficiency of 52.8% and a singlet oxygen quantum yield of 43.0%, enabling synergistic photothermal and photodynamic therapy. In vitro, IDIC NPs show negligible dark toxicity but induce potent tumor cell ablation upon irradiation through mitochondrial membrane disruption and immunogenic cell death, evidenced by calreticulin exposure, HMGB1 release, and ATP secretion. In vivo, they enable effective NIR imaging, inhibit tumor growth, prolong survival, and cause minimal systemic toxicity. Laser‐treated tumors exhibit enhanced apoptosis, reduced proliferation, and macrophage polarization toward an M1 phenotype. These findings establish IDIC NPs as a robust, single‐component nanotheranostic agent integrating NIR imaging, photothermal/photodynamic synergy, and immune activation for cancer treatment.
- Open Access
- 1 August 2024
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 17, 3835-3847
A Machine Learning Method for Differentiation Crohn’s Disease and Intestinal Tuberculosis
Background: Whether machine learning (ML) can assist in the diagnosis of Crohn’s disease (CD) and intestinal tuberculosis (ITB) remains to be explored. Methods: We collected clinical data from 241 patients, and 51 parameters were included. Six ML methods were tested, including logistic regression, decision tree, k-nearest neighbor, multinomial NB, multilayer perceptron, and XGBoost. SHAP and LIME were subsequently introduced as interpretability methods. The ML model was tested in a real-world clinical practice and compared with a multidisciplinary team (MDT) meeting. Results: XGBoost displays the best performance among the six ML models. The diagnostic AUROC and the accuracy of XGBoost were 0.946 and 0.884, respectively. The top three clinical features affecting our ML model’s result prediction were T-spot, pulmonary tuberculosis, and onset age. The ML model’s accuracy, sensitivity, and specificity in clinical practice were 0.860, 0.833, and 0.871, respectively. The agreement rate and kappa coefficient of the ML and MDT methods were 90.7% and 0.780, respectively (P< 0.001). Conclusion: We developed an ML model based on XGBoost. The ML model could provide effective and efficient differential diagnoses of ITB and CD with diagnostic bases. The ML model performs well in real-world clinical practice, and the agreement between the ML model and MDT is strong.
- 1 August 2024
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 17, 3835-3847
Open AccessA Machine Learning Method for Differentiation Crohn’s Disease and Intestinal Tuberculosis
Background: Whether machine learning (ML) can assist in the diagnosis of Crohn’s disease (CD) and intestinal tuberculosis (ITB) remains to be explored. Methods: We collected clinical data from 241 patients, and 51 parameters were included. Six ML methods were tested, including logistic regression, decision tree, k-nearest neighbor, multinomial NB, multilayer perceptron, and XGBoost. SHAP and LIME were subsequently introduced as interpretability methods. The ML model was tested in a real-world clinical practice and compared with a multidisciplinary team (MDT) meeting. Results: XGBoost displays the best performance among the six ML models. The diagnostic AUROC and the accuracy of XGBoost were 0.946 and 0.884, respectively. The top three clinical features affecting our ML model’s result prediction were T-spot, pulmonary tuberculosis, and onset age. The ML model’s accuracy, sensitivity, and specificity in clinical practice were 0.860, 0.833, and 0.871, respectively. The agreement rate and kappa coefficient of the ML and MDT methods were 90.7% and 0.780, respectively (P< 0.001). Conclusion: We developed an ML model based on XGBoost. The ML model could provide effective and efficient differential diagnoses of ITB and CD with diagnostic bases. The ML model performs well in real-world clinical practice, and the agreement between the ML model and MDT is strong.
- Open Access
- 30 November 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-15
Pan-Cancer Analysis of the Cuproptosis-Related Gene DLD
Background. Cancer affects millions of people each year and imposes a huge economic and social burden worldwide. Cuproptosis is a recently discovered novel mode of cell death. The exact function of the cuproptosis-related gene dihydrolipoamide dehydrogenase (DLD) and its role in pan-cancer is unknown. Methods. Data were retrieved from the GTEx, TCGA, and multiple online websites. These data were used to assess the expression, prognosis, and diagnostic value of DLD in various tumors. The relationship of DLD with immune microenvironment immunomodulators, immune checkpoints, tumor mutational load (TMB), microsatellite instability (MSI), and oncology drug sensitivity was explored by correlation analysis. Results. The mRNA and protein expression of DLD differs in most cancers. Survival analysis showed that DLD was associated with prognosis with KIRC, KIRP, KICH, and UCS. DLD had a strong diagnostic value in KIRC, GBM, PAAD, and LGG (AUC0.9). DLD promoter methylation affects the aberrant expression of LIHC, LUSC, PAAD, READ, and THCA. DLD was negatively correlated with stromal score, immune score, and ESTIMATE score in UCEC, TGCT, LUSC, and SARC. In UCS, resting memory CD4 T cells and activated NK cells were significantly correlated with DLD expression. Significant correlations were also observed between DLD expression and immunomodulators, immune checkpoints, TMB, and MSI in various cancers. Importantly, we also identified a number of potential drugs that may target DLD. Conclusion. DLD expression is associated with a variety of tumor prognoses and plays an integral role in tumorigenesis, tumor metabolism, and immunity.
- 30 November 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-15
Open AccessPan-Cancer Analysis of the Cuproptosis-Related Gene DLD
Background. Cancer affects millions of people each year and imposes a huge economic and social burden worldwide. Cuproptosis is a recently discovered novel mode of cell death. The exact function of the cuproptosis-related gene dihydrolipoamide dehydrogenase (DLD) and its role in pan-cancer is unknown. Methods. Data were retrieved from the GTEx, TCGA, and multiple online websites. These data were used to assess the expression, prognosis, and diagnostic value of DLD in various tumors. The relationship of DLD with immune microenvironment immunomodulators, immune checkpoints, tumor mutational load (TMB), microsatellite instability (MSI), and oncology drug sensitivity was explored by correlation analysis. Results. The mRNA and protein expression of DLD differs in most cancers. Survival analysis showed that DLD was associated with prognosis with KIRC, KIRP, KICH, and UCS. DLD had a strong diagnostic value in KIRC, GBM, PAAD, and LGG (AUC0.9). DLD promoter methylation affects the aberrant expression of LIHC, LUSC, PAAD, READ, and THCA. DLD was negatively correlated with stromal score, immune score, and ESTIMATE score in UCEC, TGCT, LUSC, and SARC. In UCS, resting memory CD4 T cells and activated NK cells were significantly correlated with DLD expression. Significant correlations were also observed between DLD expression and immunomodulators, immune checkpoints, TMB, and MSI in various cancers. Importantly, we also identified a number of potential drugs that may target DLD. Conclusion. DLD expression is associated with a variety of tumor prognoses and plays an integral role in tumorigenesis, tumor metabolism, and immunity.